← Back
Data updated: Mar 29, 2026
Sanofi
SNY MetabolicOncologyInfectious Disease
Big Pharma
French pharma with diverse portfolio spanning vaccines (Fluzone), immunology (Dupixent), and rare diseases (Fabrazyme). Growing focus on immunology.
$46.1B
Revenue (2024)
$130.0B
Market Cap
-
Trials
56
Approved (2yr)
Key Drugs
KEVZARA
sarilumab
IL-6R 3 indications · 2017
AUBAGIO
teriflunomide
Dihydroorotate dehydrogenase 3 indications · 2012
ZALTRAP
ziv-aflibercept
PlGF 1 indications · 2012
QFITLIA
fitusiran sodium
AT mRNA 2 indications · 2025
TOUJEO SOLOSTAR
insulin glargine recombinant
· 2015
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Competitive Matchups Pro
Loading...
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Metabolic 29%
7 drugs Phase 3: 26 Phase 2: 8 Phase 1: 50
Oncology 23%
9 drugs Phase 3: 8 Phase 2: 21 Phase 1: 36
Infectious Disease 19%
1 drugs Phase 3: 24 Phase 2: 10 Phase 1: 13
Immunology 15%
2 drugs Phase 3: 9 Phase 2: 23 Phase 1: 13
Respiratory 14%
3 drugs Phase 3: 14 Phase 2: 11 Phase 1: 8
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Merck big-pharma
Oncology, Infectious Disease, Immunology, Metabolic
Johnson & Johnson big-pharma
Oncology, Immunology, Infectious Disease, Metabolic
GSK big-pharma
Infectious Disease, Respiratory, Oncology, Immunology
AstraZeneca big-pharma
Oncology, Respiratory, Metabolic, Immunology
Pfizer big-pharma
Oncology, Infectious Disease, Immunology
Active (40)
WAYRILZ QFITLIA XENPOZYME NEXVIAZYME FEXINIDAZOLE SARCLISA KEVZARA TOUJEO SOLOSTAR TOUJEO MAX SOLOSTAR CERDELGA AUBAGIO ZALTRAP CAPRELSA JEVTANA KIT LUMIZYME MULTAQ MOZOBIL RENVELA MYOZYME APIDRA SOLOSTAR APIDRA FABRAZYME ELITEK LEMTRADA CAMPATH LANTUS SOLOSTAR LANTUS FERRLECIT THYROGEN ARAVA LEUPROLIDE ACETATE PRIFTIN PLAVIX AVAPRO CEREZYME LOVENOX (PRESERVATIVE FREE) LOVENOX DIABETA RIFADIN PRIMAQUINE
Discontinued (87)
RIFATER AVALIDE HECTOROL CYANOCOBALAMIN RENAGEL ELOXATIN TAXOTERE ISUPREL CLOLAR GLYBURIDE (MICRONIZED) LOZOL RIFAMATE FLOMAX AMARYL ARALEN ARALEN HYDROCHLORIDE LASIX CLOMID KETEK CLAFORAN MYTELASE NEGGRAM DANOCRINE KERLEDEX KERLONE TALACEN TALWIN NX FLUDARA SKELID PHISOHEX OFORTA TRANCOPAL TORNALATE CALCIMAR BRICANYL TENUATE INOCOR PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER PRIMACOR CANTIL NASACORT HFA INTAL TILADE PENETREX ORNIDYL CERUBIDINE SLO-PHYLLIN SLO-BID LOTUSATE NITRO-BID
+37 more
Company Info
- First Approval
- 1948-02-19
- Latest
- 2026-02-11
- Applications
- 152
FDA Sponsor Names
SANOFI AVENTIS USGENZYME CORPGENZYMESANOFISANOFI SYNTHELABO +1